Ocelot Bio is a brand dedicated to revolutionizing the treatment of end-stage liver disease (ESLD) through the development of therapeutic peptides. With a focus on improving patient outcomes, Ocelot Bio combines expertise in therapeutic peptide drug formulation and breakthrough science to bring forward novel medical innovations. The brand's lead asset, OCE-205, is a therapeutic peptide designed to address complications of ESLD, such as hepatorenal syndrome with acute kidney injury (HRS-AKI) and ascites.

By improving renal function and prolonging survival, OCE-205 aims to provide patients with HRS-AKI the opportunity to access liver transplantation, enhance transplant outcomes, and reduce the need for combined liver and kidney transplants. Ocelot Bio has already initiated a Phase 2 clinical trial for OCE-205 in HRS-AKI and has received Orphan Drug Designation from the U. S.

Food & Drug Administration (FDA). The brand is also in early-stage development of OCE-205 for the treatment of ascites. Driven by their patient-first mission, Ocelot Bio assembles a leadership team with extensive experience in clinical development, regulatory affairs, and building successful companies.

Their agile operating model maximizes efficiency in research and development, ensuring innovative therapies reach those in need. For more information on Ocelot Bio and their groundbreaking research, please visit their website